Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

By LabMedica International staff writers
Posted on 03 Apr 2025

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9. More...

7 billion each year. SCI imposes significant emotional and financial strain on both patients and caregivers. Diagnosing SCI and determining the potential for recovery necessitate extensive clinical evaluations and advanced imaging, which is both time-consuming and costly, especially for those with SCI-related complications. Clinicians have long been in search of a rapid, minimally invasive method that can reliably confirm the injury, assess its severity, and predict the potential for recovery. A new blood test, detailed in The Journal of Clinical Investigation, may offer a solution to this pressing need in patient care.

Researchers at Johns Hopkins University School of Medicine (Baltimore, MD, USA) have developed an innovative blood test that could quickly predict the severity of SCI and the likelihood of sensory and motor recovery within six months. This test presents a cost-effective alternative to traditional diagnostic methods. Historically, blood tests have not been seen as reliable for assessing spinal conditions due to the blood-brain barrier—a protective layer that shields the brain from harmful substances, such as viruses and bacteria, found in the blood. However, researchers speculated that SCI could disrupt this barrier, potentially allowing for detectable biomarkers in the bloodstream. Drawing on advancements in cancer biomarker research, particularly the use of liquid biopsies to detect cell-free DNA (cfDNA) and proteins, the team applied similar techniques to SCI, offering a method to guide treatment and monitor recovery progress.

The researchers analyzed blood samples from 50 individuals with acute SCI and 25 without, with 68% of the participants being male and 32% female. They observed that cfDNA levels in the blood corresponded with the American Spinal Injury Association (ASIA) scale, a standard tool for assessing SCI severity based on motor and sensory functions. The study found higher cfDNA concentrations in patients in the ASIA A group, which represents the most severe cases with no sensation or motor function. This was in contrast to less severe injuries in ASIA groups B, C, and D, indicating that greater spinal cord damage leads to more cfDNA being released into the bloodstream. To enhance the accuracy of the blood test, the researchers identified four specific plasma proteins—FABP3, REST, IL-6, and NF-H—that were elevated in patients with SCI. They combined these markers into what they termed the Spinal Cord Injury Index (SCII).

When the SCII was compared with ASIA groups, it accurately reflected the severity of injury and aligned with MRI scans and physical evaluations. Patients were monitored for six months to assess any improvements in their ASIA grade. The SCII successfully predicted with 77% accuracy which patients would experience neurological improvements. This suggests that the new blood test can potentially predict long-term recovery for most patients, addressing a central concern for those with SCI and their caregivers. The researchers believe that using the SCII to track biomarkers over time could help measure treatment effectiveness and facilitate personalized care, similar to the use of liquid biopsies in cancer patients. This multi-analyte blood test represents a promising advancement in SCI diagnostics and personalized treatment for traumatic injuries. However, additional studies are needed, and the research team plans to conduct multi-center clinical trials to further evaluate and refine the performance of this test.

“If you have a spinal cord injury, your main question is simple: Am I going to walk again?” said lead study author and neurosurgery chief resident Tej D. Azad, M.D., M.S. “With the new blood test, we are trying to bring a precision medicine framework to spinal cord injury with something that tells you about injury severity and can hopefully predict neurological recovery.”


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.